Dolutegravir Combo Beats Atripla in Head-to-Head Trial

Shionogi-ViiV Healthcare LLC's HIV drug dolutegravir beat Gilead Sciences Inc.'s Atripla in a Phase III trial in treatment-naive adults with HIV-1 infection. Initial results showed that 88 percent of patients receiving dolutegravir with Kivexa/Epzicom (abacavir/lamivudine) were virologically suppressed, compared to 81 percent on Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate).